Delighted to join for the first episode of “Precision Signals,” a new podcast by the CEO Roundtable on Cancer – Olivier Elemento

Olivier Elemento, Director of Englander Institute for Precision Medicine, shared a post by CEO Roundtable on Cancer, adding:

“I was delighted to join Dr. Sean Khozin and my esteemed colleague Dr. Cora Sternberg for the first episode of “Precision Signals,” a new podcast by the CEO Roundtable on Cancer.

Instead of focusing on the hype surrounding AI, we had a frank discussion about the real-world obstacles to its adoption. We talked about what it truly takes for a new technology to move from a publication into the daily practice of an oncologist.

Building a foundation of clinical trust is the most important part of this work. That trust can’t be built on algorithms alone; it has to be built on rigorous validation, demonstrated utility, and an unwavering focus on patient outcomes.

Our conversation covers the challenges of clinical integration, the standards for evidence we must meet, and how we can collectively build that bridge of trust. I hope you find the discussion insightful.”

Quoting CEO Roundtable on Cancer‘s post:

CEO Roundtable on Cancer proudly announces the launch of Precision Signals, a podcast series exploring the intersection of cutting-edge science, clinical practice, and patient care in modern oncology.

Episode 1: Bridging the AI Adoption Gap in Cancer Care
Our inaugural episode tackles one of oncology’s most pressing paradoxes: despite hundreds of regulatory approvals and unprecedented investment, artificial intelligence remains largely absent from routine cancer care. What accounts for this striking disconnect between regulatory success and clinical adoption?

Dr. Sean Khozin, CEO of the CEO Roundtable on Cancer, leads an illuminating discussion with two distinguished experts at the forefront of precision oncology:

Dr. Cora Sternberg, Clinical Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, brings invaluable perspective as a globally recognized oncologist and clinical trial leader whose work has transformed treatment paradigms in genitourinary cancers.

Dr. Olivier Elemento, Director of the Englander Institute for Precision Medicine, offers unique insights as a computational biologist pioneering the integration of artificial intelligence, genomics, and real-world evidence into clinically actionable frameworks.

The Critical Questions

This conversation addresses fundamental challenges facing the field, including:

• Why has regulatory approval failed to translate into widespread clinical implementation?
• What evidence standards must AI technologies meet to gain clinician confidence?
• How can we design systems that seamlessly integrate into existing clinical workflows?
• What role should real-world evidence play in validating AI-driven interventions?

Beyond the Hype: Evidence-Based Innovation
Precision Signals aims to cut through the hype to examine what truly drives progress in cancer care. Each episode features candid conversations with leaders who are not just observers of change, but architects of transformation, from laboratory discovery through regulatory approval to bedside implementation.

Listen to Episode 1: ‘AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust.’ ”

More posts featuring Olivier Elemento on OncoDaily.